tiprankstipranks

Viveve downgraded to Neutral from Buy at Alliance Global Partners

Alliance Global Partners analyst Ben Haynor downgraded Viveve Medical to Neutral from Buy and dropped coverage of the name after the company announced the pivotal PURSUIT trial in stress urinary incontinence in women did not meet its primary endpoint nor several secondary endpoints. The analyst expects little interest from potential acquirers and sees little upside for shareholders.

Confident Investing Starts Here:

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on VIVE:

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue